News
FBLG
11.35
-3.81%
-0.45
Press Release: FibroBiologics Announces 2024 Annual Meeting of Stockholders
FibroBiologics, Inc. Announces 2024 Annual Meeting of Stockholders will take place on August 27, 2024. The company is a clinical-stage biotechnology company with 150+ patents issued and pending. Fibro biologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways.
Dow Jones · 4d ago
FibroBiologics GAAP EPS of -$0.27
FibroBiologics, Inc. Q1 GAAP EPS of -$ . The Company had $6,039 thousand and no cash equivalents as of March 31, 2024 and December 31, 2023. Earnings News: Fibro biologics reported Q1 earnings of - $.
Seeking Alpha · 4d ago
FibroBiologics Announces 2024 Annual Meeting of Stockholders
FibroBiologics, Inc. Announces its 2024 Annual Meeting of Stockholders will take place on August 27, 2024. The company is a clinical-stage biotechnology company with 150+ patents issued and pending. The annual meeting will be held exclusively through a virtual format.
Barchart · 4d ago
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024
FibroBiologics, Inc. – Common Stock reported earnings per share of -27 cents for the first quarter of 2024. The company did not report any revenue for the quarter. Fibro biologics reported results for the second quarter of 24 years ago.
Investorplace · 4d ago
FibroBiologics Files 2024 First Quarter Report
Barchart · 5d ago
Weekly Report: what happened at FBLG last week (0506-0510)?
Weekly Report · 6d ago
FibroBiologics to Present at the BIO International Convention 2024
FibroBiologics, Inc. Will present a corporate update on recent business and clinical developments at the 2024 BIO International Convention, June 3-6, 2024, in San Diego. The company is a clinical-stage biotechnology company with 150+ patents issued and pending.
Barchart · 05/07 08:31
Weekly Report: what happened at FBLG last week (0429-0503)?
Weekly Report · 05/06 12:56
Weekly Report: what happened at FBLG last week (0422-0426)?
Weekly Report · 04/29 13:05
FibroBiologics files to sell 1.8M units
FibroBiologics files to sell 1.8M units Apr. 26, 2024. Each unit consists of one share, and one warrant to buy one share. Fibro biologics filed a prospectus related to the sale of 1.7M units at $11.1 per unit.
Seeking Alpha · 04/26 19:23
FIBROBIOLOGICS FILES FOR OFFERING OF UP TO 1.8 MLN UNITS, EACH CONSISTING OF ONE COMMON SHARE, ONE WARRANT TO PURCHASE ONE COMMON SHARE - SEC FILING
Reuters · 04/26 10:08
Fibrobiologics: Correspondence
Press release · 04/25 15:10
FibroBiologics, Charles River Laboratories Sign Letter Of Intent Allowing For Transfer, Testing And Validation Of Technology
Charles River and FibroBiologics will enter into an anticipated master services agreement. Charles River will conduct feasibility studies on fibroblast-based cell manufacturing processes. The company will be responsible for producing drug products for certain Fibro biologics' clinical trials. This comes ahead of entering into a contract with Charles River.
Benzinga · 04/25 12:02
FIBROBIOLOGICS PLANS TO COLLABORATE WITH CHARLES RIVER TO MANUFACTURE FIBROBLAST-BASED SPHEROIDS
Reuters · 04/25 12:00
Weekly Report: what happened at FBLG last week (0415-0419)?
Weekly Report · 04/22 12:45
Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
Ally Financial shares jumped 7.7% to $39.06 on Thursday after the company reported better-than-expected quarterly results. The Nasdaq Composite fell over 50 points in today's session. Shares of Trump Media & Technology Group Corp. Also rose sharply.
Benzinga · 04/18 17:58
Weekly Report: what happened at FBLG last week (0408-0412)?
Weekly Report · 04/15 12:34
FIBROBIOLOGICS GRANTED PATENT FOR REGENERATION OF CARTILAGE-TYPE CELLS BY THE AUSTRALIAN PATENT OFFICE
Reuters · 04/11 13:31
Weekly Report: what happened at FBLG last week (0401-0405)?
Weekly Report · 04/08 12:42
FibroBiologics Presents Data From Dermal Fibroblast Spheroid-Based Treatment Of Chronic Wounds In A Diabetes Mouse Model At Advanced Wound Care Summit USA
FibroBiologics, Inc. Is a clinical-stage biotechnology company with 150+ patents for the development of fibroblasts and fibroblast-derived materials. The company has completed a study in a diabetes mouse model on the potential therapeutic efficacy of dermal fibro blast spheroids in treating chronic wounds. The findings will be presented at the Advanced Wound Care Summit USA in Boston, April 16-17. Diabetic foot ulcers are prevalent in people with diabetes.
Benzinga · 04/04 13:32
More
Webull provides a variety of real-time FBLG stock news. You can receive the latest news about Fibrobiologics through multiple platforms. This information may help you make smarter investment decisions.
About FBLG
FibroBiologics Inc is a United States-based company. The Company operates as a biopharmaceutical company. It is focused on developing and commercializing fibroblast cell-based therapies for patients suffering from chronic diseases. It also develops biologic cures and treatments for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing, and cancer, and anti-aging extension of life applications such as thymic involution reversal and splenic involution reversal.